# Pro Dex Inc: financial statements, quarterly

PDEX · Nasdaq · CIK 788920 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/pdex.md) · [Financials](/companies/pdex/financials.md) · [Filings](/companies/pdex/filings.md) · [Insiders](/companies/pdex/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pdex/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [12.6](/filings/0001079973-25-000164.md) | [14.3](/filings/0001079973-25-000729.md) | [15.0 d](/filings/0001079973-25-001426.md) | [14.9](/filings/0001079973-25-001655.md) | [16.8](/filings/0001079973-26-000140.md) | [17.4](/filings/0001079973-26-000580.md) | [17.5 d](/filings/0001079973-26-001215.md) | [18.5](/filings/0001079973-26-001410.md) | [18.7](/filings/0001079973-26-000140.md) | [19.9](/filings/0001079973-26-000580.md) | [20.4 d](/filings/0001079973-26-001215.md) | [20.6](/filings/0001079973-26-001410.md) |
| Cost of revenue | $m | [9.8](/filings/0001079973-25-000164.md) | [10.3](/filings/0001079973-25-000729.md) | [10.9 d](/filings/0001079973-25-001426.md) | [9.7](/filings/0001079973-25-001655.md) | [11.7](/filings/0001079973-26-000140.md) | [11.6](/filings/0001079973-26-000580.md) | [14.0 d](/filings/0001079973-26-001215.md) | [13.2](/filings/0001079973-26-001410.md) | [12.9](/filings/0001079973-26-000140.md) | [13.8](/filings/0001079973-26-000580.md) | [13.3 d](/filings/0001079973-26-001215.md) | [13.7](/filings/0001079973-26-001410.md) |
| Gross profit | $m | [2.8](/filings/0001079973-25-000164.md) | [4.0](/filings/0001079973-25-000729.md) | [4.1 d](/filings/0001079973-25-001426.md) | [5.2](/filings/0001079973-25-001655.md) | [5.1](/filings/0001079973-26-000140.md) | [5.8](/filings/0001079973-26-000580.md) | [3.5 d](/filings/0001079973-26-001215.md) | [5.4](/filings/0001079973-26-001410.md) | [5.7](/filings/0001079973-26-000140.md) | [6.1](/filings/0001079973-26-000580.md) | [7.1 d](/filings/0001079973-26-001215.md) | [6.9](/filings/0001079973-26-001410.md) |
| Research and development | $m | [0.8](/filings/0001079973-25-000164.md) | [0.8](/filings/0001079973-25-000729.md) | [0.8 d](/filings/0001079973-25-001426.md) | [0.8](/filings/0001079973-25-001655.md) | [0.9](/filings/0001079973-26-000140.md) | [0.9](/filings/0001079973-26-000580.md) | [0.9 d](/filings/0001079973-26-001215.md) | [0.8](/filings/0001079973-26-001410.md) | [0.7](/filings/0001079973-26-000140.md) | [0.8](/filings/0001079973-26-000580.md) | [1.0 d](/filings/0001079973-26-001215.md) | [1.2](/filings/0001079973-26-001410.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | [1.4](/filings/0001079973-26-000140.md) | [1.2](/filings/0001079973-26-000580.md) | [1.2 d](/filings/0001079973-26-001215.md) | [1.5](/filings/0001079973-26-001410.md) | [1.8](/filings/0001079973-26-000140.md) | [2.2](/filings/0001079973-26-000580.md) | [2.5 d](/filings/0001079973-26-001215.md) | [2.1](/filings/0001079973-26-001410.md) |
| Operating income | $m | [0.8](/filings/0001079973-25-000164.md) | [2.2](/filings/0001079973-25-000729.md) | [2.4 d](/filings/0001079973-25-001426.md) | [3.0](/filings/0001079973-25-001655.md) | [2.7](/filings/0001079973-26-000140.md) | [3.6](/filings/0001079973-26-000580.md) | [1.3 d](/filings/0001079973-26-001215.md) | [3.1](/filings/0001079973-26-001410.md) | [3.3](/filings/0001079973-26-000140.md) | [3.1](/filings/0001079973-26-000580.md) | [3.5 d](/filings/0001079973-26-001215.md) | [3.5](/filings/0001079973-26-001410.md) |
| Interest expense | $m | [0.1](/filings/0001079973-25-000164.md) | [0.1](/filings/0001079973-25-000729.md) | [0.1 d](/filings/0001079973-25-001426.md) | [0.2](/filings/0001079973-25-001655.md) | [0.2](/filings/0001079973-26-000140.md) | [0.2](/filings/0001079973-26-000580.md) | [0.2 d](/filings/0001079973-26-001215.md) | [0.2](/filings/0001079973-25-001655.md) | [0.1](/filings/0001079973-26-000140.md) | [0.2](/filings/0001079973-26-000580.md) | [0.3 d](/filings/0001079973-26-001215.md) | [0.3](/filings/0001079973-26-001410.md) |
| Income tax | $m | [0.1](/filings/0001079973-25-000164.md) | [0.3](/filings/0001079973-25-000729.md) | [0.3 d](/filings/0001079973-25-001426.md) | [0.9](/filings/0001079973-25-001655.md) | [0.5](/filings/0001079973-26-000140.md) | [1.3](/filings/0001079973-26-000580.md) | [0.4 d](/filings/0001079973-26-001215.md) | [1.5](/filings/0001079973-26-001410.md) | [0.7](/filings/0001079973-26-000140.md) | [1.4](/filings/0001079973-26-000580.md) | [0.7 d](/filings/0001079973-26-001215.md) | [0.3](/filings/0001079973-26-001410.md) |
| Net income | $m | [0.5](/filings/0001079973-25-000164.md) | [0.7](/filings/0001079973-25-000729.md) | [1.6 d](/filings/0001079973-25-001426.md) | [2.5](/filings/0001079973-25-001655.md) | [2.0](/filings/0001079973-26-000140.md) | [3.3](/filings/0001079973-26-000580.md) | [1.2 d](/filings/0001079973-26-001215.md) | [4.7](/filings/0001079973-26-001410.md) | [2.2](/filings/0001079973-26-000140.md) | [3.9](/filings/0001079973-26-000580.md) | [2.9 d](/filings/0001079973-26-001215.md) | [3.0](/filings/0001079973-26-001410.md) |
| Diluted EPS | $ per share | [0.14](/filings/0001079973-25-000164.md) | [0.19](/filings/0001079973-25-000729.md) | not reported | [0.75](/filings/0001079973-25-001655.md) | [0.61](/filings/0001079973-26-000140.md) | [0.98](/filings/0001079973-26-000580.md) | not reported | [1.40](/filings/0001079973-26-001410.md) | [0.66](/filings/0001079973-26-000140.md) | [1.20](/filings/0001079973-26-000580.md) | not reported | [0.92](/filings/0001079973-26-001410.md) |
| Basic EPS | $ per share | [0.14](/filings/0001079973-25-000164.md) | [0.19](/filings/0001079973-25-000729.md) | not reported | [0.76](/filings/0001079973-25-001655.md) | [0.63](/filings/0001079973-26-000140.md) | [1.00](/filings/0001079973-26-000580.md) | not reported | [1.43](/filings/0001079973-26-001410.md) | [0.67](/filings/0001079973-26-000140.md) | [1.23](/filings/0001079973-26-000580.md) | not reported | [0.95](/filings/0001079973-26-001410.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.3](/filings/0001079973-24-000181.md) | [3.2](/filings/0001079973-24-000639.md) | [2.6](/filings/0001079973-25-001426.md) | [3.1](/filings/0001079973-24-001462.md) | [0.1](/filings/0001079973-25-000164.md) | [0.0](/filings/0001079973-25-000729.md) | [0.4](/filings/0001079973-26-001215.md) | [0.0](/filings/0001079973-25-001655.md) | [5.3](/filings/0001079973-26-000140.md) | [6.6](/filings/0001079973-26-000580.md) | [8.2](/filings/0001079973-26-001410.md) | [11.8](/filings/0001079973-26-001410.md) |
| Current assets | $m | [36.6](/filings/0001079973-24-000181.md) | [36.0](/filings/0001079973-24-000639.md) | [36.6](/filings/0001079973-25-001426.md) | [38.5](/filings/0001079973-24-001462.md) | [44.3](/filings/0001079973-25-000164.md) | [49.9](/filings/0001079973-25-000729.md) | [47.3](/filings/0001079973-26-001215.md) | [50.7](/filings/0001079973-25-001655.md) | [49.2](/filings/0001079973-26-000140.md) | [53.7](/filings/0001079973-26-000580.md) | [53.2](/filings/0001079973-26-001410.md) | [53.9](/filings/0001079973-26-001410.md) |
| Total assets | $m | [51.4](/filings/0001079973-24-000181.md) | [50.5](/filings/0001079973-24-000639.md) | [52.5](/filings/0001079973-25-001426.md) | [54.3](/filings/0001079973-24-001462.md) | [60.4](/filings/0001079973-25-000164.md) | [64.3](/filings/0001079973-25-000729.md) | [61.2](/filings/0001079973-26-001215.md) | [64.3](/filings/0001079973-25-001655.md) | [62.3](/filings/0001079973-26-000140.md) | [75.0](/filings/0001079973-26-000580.md) | [74.5](/filings/0001079973-26-001410.md) | [76.6](/filings/0001079973-26-001410.md) |
| Current liabilities | $m | [10.0](/filings/0001079973-24-000181.md) | [10.4](/filings/0001079973-24-000639.md) | [12.9](/filings/0001079973-25-001426.md) | [11.3](/filings/0001079973-24-001462.md) | [17.1](/filings/0001079973-25-000164.md) | [18.3](/filings/0001079973-25-000729.md) | [14.6](/filings/0001079973-26-001215.md) | [13.6](/filings/0001079973-25-001655.md) | [12.2](/filings/0001079973-26-000140.md) | [14.6](/filings/0001079973-26-000580.md) | [13.0](/filings/0001079973-26-001410.md) | [12.9](/filings/0001079973-26-001410.md) |
| Total liabilities | $m | [19.6](/filings/0001079973-24-000181.md) | [19.6](/filings/0001079973-24-000639.md) | [21.6](/filings/0001079973-25-001426.md) | [23.4](/filings/0001079973-24-001462.md) | [28.6](/filings/0001079973-25-000164.md) | [29.0](/filings/0001079973-25-000729.md) | [24.6](/filings/0001079973-26-001215.md) | [22.8](/filings/0001079973-25-001655.md) | [20.6](/filings/0001079973-26-000140.md) | [29.8](/filings/0001079973-26-000580.md) | [26.9](/filings/0001079973-26-001410.md) | [27.2](/filings/0001079973-26-001410.md) |
| Long-term debt | $m | not reported | not reported | [12.0](/filings/0001553350-24-000079.md) | not reported | not reported | not reported | [15.4](/filings/0001079973-25-001426.md) | not reported | not reported | not reported | [17.5](/filings/0001079973-26-001215.md) | not reported |
| Shareholders' equity | $m | [31.8](/filings/0001079973-25-000729.md) | [30.9](/filings/0001079973-25-000729.md) | [30.9](/filings/0001079973-26-001215.md) | [30.9](/filings/0001079973-26-000140.md) | [31.8](/filings/0001079973-26-000580.md) | [35.3](/filings/0001079973-26-000580.md) | [36.6](/filings/0001079973-26-001410.md) | [41.5](/filings/0001079973-26-001410.md) | [41.6](/filings/0001079973-26-000580.md) | [45.2](/filings/0001079973-26-000580.md) | [47.6](/filings/0001079973-26-001410.md) | [49.3](/filings/0001079973-26-001410.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [710 d](/filings/0001079973-25-000164.md) | [4,077 d](/filings/0001079973-25-000729.md) | [1,045 d](/filings/0001079973-25-001426.md) | [1,887](/filings/0001079973-25-001655.md) | [(4,150) d](/filings/0001079973-26-000140.md) | [754 d](/filings/0001079973-26-000580.md) | [(173) d](/filings/0001079973-26-001215.md) | [2,310](/filings/0001079973-26-001410.md) | [3,572 d](/filings/0001079973-26-000140.md) | [1,633 d](/filings/0001079973-26-000580.md) | [(273) d](/filings/0001079973-26-001215.md) | [6,490](/filings/0001079973-26-001410.md) |
| Capital expenditure | $k | [633 d](/filings/0001079973-25-000164.md) | [117 d](/filings/0001079973-25-000729.md) | not reported | [431](/filings/0001079973-25-001655.md) | [542 d](/filings/0001079973-26-000140.md) | [180 d](/filings/0001079973-26-000580.md) | [93.0 d](/filings/0001079973-26-001215.md) | [98.0](/filings/0001079973-26-001410.md) | [70.0 d](/filings/0001079973-26-000140.md) | [112 d](/filings/0001079973-26-000580.md) | [203 d](/filings/0001079973-26-001215.md) | [346](/filings/0001079973-26-001410.md) |
| Share repurchases | $k | not reported | [1,723 d](/filings/0001079973-25-000729.md) | [1,675 d](/filings/0001079973-25-001426.md) | [2,311](/filings/0001079973-25-001655.md) | [1,193 d](/filings/0001079973-26-000140.md) | [0.0 d](/filings/0001079973-26-000580.md) | [0.0 d](/filings/0001079973-26-001215.md) | not reported | not reported | [601 d](/filings/0001079973-26-000580.md) | [600 d](/filings/0001079973-26-001215.md) | [600](/filings/0001079973-26-001410.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q1 FY2027 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [3,652](/filings/0001079973-24-000181.md) | [3.6](/filings/0001079973-24-000639.md) | [3,547](/filings/0001079973-24-001462.md) | [3,612](/filings/0001079973-25-000164.md) | [3,524](/filings/0001079973-25-000729.md) | [3,292](/filings/0001079973-25-001655.md) | [3,337](/filings/0001079973-26-000140.md) | [3,337](/filings/0001079973-26-000580.md) | [3,339](/filings/0001079973-26-001410.md) | [3,304](/filings/0001079973-26-000140.md) | [3,270](/filings/0001079973-26-000580.md) | [3,315](/filings/0001079973-26-001410.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,200,001 at 2026-10-28, from the cover of the [10-Q filed 2026-10-29](/filings/0001079973-26-001410.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 16:35 ET. No prices; not investment advice.